Takeda Pharmaceutical Co Stock Book Value Per Share
TKPHF Stock | USD 25.12 0.67 2.74% |
Takeda Pharmaceutical Co fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Pink Sheet. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical pink sheet.
Takeda |
Takeda Pharmaceutical Co Company Book Value Per Share Analysis
Takeda Pharmaceutical's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Takeda Pharmaceutical Book Value Per Share | 3,973 X |
Most of Takeda Pharmaceutical's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Competition |
In accordance with the recently published financial statements, the book value per share of Takeda Pharmaceutical Co is about 3.97 K times. This is 233800.29% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The book value per share for all United States stocks is 105.68% lower than that of the firm.
Takeda Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takeda Pharmaceutical's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics of similar companies.Takeda Pharmaceutical is currently under evaluation in book value per share category among its peers.
Takeda Fundamentals
Return On Equity | 0.0477 | |||
Return On Asset | 0.0247 | |||
Profit Margin | 0.07 % | |||
Operating Margin | 0.13 % | |||
Current Valuation | 75.53 B | |||
Shares Outstanding | 1.56 B | |||
Shares Owned By Insiders | 1.20 % | |||
Shares Owned By Institutions | 41.35 % | |||
Price To Earning | 27.54 X | |||
Price To Book | 0.97 X | |||
Price To Sales | 0.01 X | |||
Revenue | 3.57 T | |||
Gross Profit | 2.44 T | |||
EBITDA | 1.05 T | |||
Net Income | 230.06 B | |||
Cash And Equivalents | 645.99 B | |||
Cash Per Share | 417.82 X | |||
Total Debt | 4.14 T | |||
Debt To Equity | 0.81 % | |||
Current Ratio | 1.18 X | |||
Book Value Per Share | 3,973 X | |||
Cash Flow From Operations | 1.12 T | |||
Earnings Per Share | 1.33 X | |||
Price To Earnings To Growth | 0.58 X | |||
Number Of Employees | 47.35 K | |||
Beta | 0.7 | |||
Market Capitalization | 50.37 B | |||
Total Asset | 13.18 T | |||
Retained Earnings | 1.57 T | |||
Working Capital | 675.58 B | |||
Current Asset | 1.48 T | |||
Current Liabilities | 808.72 B | |||
Annual Yield | 0.04 % | |||
Five Year Return | 3.99 % | |||
Net Asset | 13.18 T | |||
Last Dividend Paid | 180.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Takeda Pink Sheet
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.